Prevalence of chronic kidney disease, end-stage kidney disease and Kidney Disease: Improving Global Outcomes risk groups among First Nations people and other people in Ontario as of Sept. 30, 2015
| Variable | First Nations people | Other people in Crude prevalence, no. (%) | |
|---|---|---|---|
| Ontario, prevalence, no. (%) | Age- and sex-standardized prevalence, % (95% CI) | ||
| n = 15 344* | n = 1 103 739* | ||
| Chronic kidney disease (based on eGFR < 60 mL/min per 1.73 m2) | 2121 (13.8) | 20.7 (19.9–21.5) | 202 772 (18.4) |
| End-stage kidney disease (based on eGFR < 15 mL/min per 1.73 m2) | 113 (0.7) | 0.8 (0.7–1.0) | 3000 (0.3) |
| Treatment for end-stage kidney disease | n = 21 968 | n = 1 302 177 | |
| Receipt of kidney transplant | 67 (0.3) | 0.4 (0.3–0.5) | 2627 (0.2) |
| Receipt of long-term dialysis | 355 (1.6) | 1.7 (1.5–1.9) | 7161 (0.5) |
| Risk of kidney-disease–related adverse events (based on KDIGO)16 | n = 10 746† | n = 768 569† | |
| Low‡ | 6191 (57.6) | 51.7 (50.7–52.7) | 490 934 (63.9) |
| Moderately increased§ | 2642 (24.6) | 25.3 (24.4–26.3) | 163 692 (21.3) |
| High¶ | 1099 (10.2) | 12.0 (11.3–12.8) | 64 250 (8.4) |
| Very high** | 814 (7.6) | 10.8 (10.0–11.5) | 49 693 (6.5) |
Note: CI = confidence interval, eGFR = estimated glomerular filtration rate, KDIGO = Kidney Disease: Improving Global Outcomes.
↵* Analysis restricted to people with a serum creatinine value.
↵† Analysis restricted to people with both serum creatinine and urine albumin-to-creatinine ratio (ACR) values.
↵‡ Defined as eGFR ≥ 90 mL/min per 1.73 m2 with ACR < 3 mg/mmol, or eGFR 60 to < 90 mL/min per 1.73 m2 with ACR < 3 mg/mmol.
↵§ Defined as eGFR ≥ 90 mL/min per 1.73 m2 with ACR 3–30 mg/mmol, eGFR 60 to < 90 mL/min per 1.73 m2 with ACR 3–30 mg/mmol, or eGFR 45 to < 60 mL/min per 1.73 m2 with ACR < 3 mg/mmol.
↵¶ Defined as eGFR ≥ 90 mL/min per 1.73 m2 with ACR > 30 mg/mmol, eGFR 60 to < 90 mL/min per 1.73 m2 with ACR > 30 mg/mmol, eGFR 45 to < 60 mL/min per 1.73 m2 with ACR 3–30 mg/mmol, or eGFR 30 to < 45 mL/min per 1.73 m2 with ACR < 3 mg/mmol.
↵** Defined as eGFR 45 to < 60 mL/min per 1.73 m2 with ACR > 30 mg/mmol, eGFR 30 to < 45 mL/min per 1.73 m2 with ACR 3–30 mg/mmol, eGFR 30 to < 45 mL/min per 1.73 m2 with ACR > 30 mg/mmol, eGFR 15 to < 30 mL/min per 1.73 m2 with ACR < 3 mg/mmol, eGFR 15 to < 30 mL/min per 1.73 m2 with ACR 3–30 mg/mmol, eGFR 15 to < 30 mL/min per 1.73 m2 with ACR > 30 mg/mmol, eGFR < 15 mL/min per 1.73 m2 with ACR < 3 mg/mmol, eGFR < 15 mL/min per 1.73 m2 with ACR 3–30 mg/mmol, or eGFR < 15 mL/min per 1.73 m2 with ACR > 30 mg/mmol.